诱导化疗在进展期头颈部鳞癌中的应用现状和研究进展  

Research progress of induction chemotherapy in advanced head and neck squamous cell carcinoma

作　　者：张泽 张仑 王旭东 Ze Zhang;Lun Zhang;Xudong Wang(Department of Head and Neck Oncology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院颌面耳鼻喉肿瘤科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,天津市300060

出　　处：《中国肿瘤临床》2021年第24期1272-1276,共5页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金项目(编号:81902757);天津医科大学肿瘤医院临床试验基金项目(编号:C1715/C1716)资助。

摘　　要：头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)是常见的恶性肿瘤。诱导化疗作为治疗进展期HNSCC的主要手段之一,得到广泛研究并应用于临床。然而,除了在器官保留方面以外,诱导化疗能否为患者带来获益一直存在争议。目前,TPF方案(多西他赛+顺铂+5-氟尿嘧啶)仍然是HNSCC诱导化疗的标准方案,但是TPF方案具有不良反应较大等问题。近年来,围绕着诱导化疗在进展期HNSCC的应用,产生较多的研究报道和循证医学证据。本文通过非系统性检索近年来所有进展期HNSCC诱导化疗的文献,就该领域研究现状进行综述,探讨诱导化疗标准方案的建立和其对患者生存及器官保留的临床意义,总结减少化疗相关不良反应的尝试,分析新的诱导化疗方案。Head and neck squamous cell carcinoma(HNSCC)is a common malignancy.Induction chemotherapy in advanced HNSCC has been extensively investigated.However,the role of induction chemotherapy outside of laryngeal preservation is unclear.Presently,docetaxel-cisplatin-fluorouracil(TPF regimen)is still the standard regimen for induction chemotherapy.Recently,more evidence has been accumulated regarding the application of induction chemotherapy in locally advanced HNSCC.In this review,we non-systematically evaluated recently published studies on induction chemotherapy in various patient populations with locally advanced HNSCC,providing an overview of the effect of induction chemotherapy on survival results and organ preservation,the exact patient subgroups who may benefit from induction chemotherapy,and how to reduce toxicity and which new regimens present promising results.

关 键 词：头颈部鳞癌 诱导化疗 TPF方案 器官保留 毒性 

分 类 号：R739.91[医药卫生—肿瘤]